Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up

Molinaro, Eleonora; Giani, Carlotta; Agate, Laura; Biagini, Agnese; Pieruzzi, Letizia; Bianchi, Francesca; Brozzi, Federica; Ceccarelli, Claudia; Viola, David; Piaggi, Paolo; Vitti, Paolo; Pacini, Furio; Elisei, Rossella

doi:10.1210/jc.2012-4137

Cited by 61 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…rhTSH is expensive; hence, there is considerable controversy surrounding the cost-effectiveness of using rhTSH [17]. However, the ablation success rate by the proposed method is comparable to that obtained using thyroid hormone withdrawal, even in high-risk patients with metastatic thyroid cancer; the long-term outcome is also similar between both protocols [18][19][20]. Therefore, it is recommended that rhTSH be applied routinely for RIT to improve patient QOL.…”

Section: Discussionmentioning

confidence: 92%

Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?

Bang

Lee

Kim

2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Objectives Recombinant human thyroid-stimulating hormone (rhTSH) is widely used in radioactive iodine therapy (RIT) to avoid side effects caused by hypothyroidism during the therapy. Owing to RIT with rhTSH, serum thyroglobulin (Tg) is measured with high 131 I concentrations. It is of concern that the relatively high energy of 131 I could interfere with Tg measurement using the immunoradiometric assay (IRMA). We investigated the effect of 131 I administration on Tg measurement with IRMA after RIT. Methods A total of 67 patients with thyroid cancer were analysed retrospectively. All patients had undergone rhTSH stimulation for RIT. The patients' sera were sampled 2 days after 131 I administration and divided into two portions: for Tg measurements on days 2 and 32 after 131 I administration. The count per minute (CPM) of whole serum (200 μl) was also measured at each time point. Student's paired t-test and Pearson's correlation analyses were performed for statistical analysis. Results Serum Tg levels were significantly concordant between days 2 and 32, irrespective of the serum CPM. Subgroup analysis was performed by classification based on the 131 I dose. No difference was noted between the results of the two groups.Conclusions IRMA using 125 I did not show interference from 131

show abstract

Section: Discussionmentioning

confidence: 92%

Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?

Bang

Lee

Kim

2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…thyroid disease, such as subacute thyroiditis (Hidaka et al, 1994), Graves' disease (Izumi and Larsen, 1978), and thyrotoxicosis factitia (Mariotti et al, 1982), or among people with a history of thyroid cancer (Ericsson et al, 1984;Haugen et al, 2016;Heemstra et al, 2007;McGrath et al, 2015;Molinaro et al, 2013;Rosario et al, 2013;Trimboli et al, 2015). While several epidemiologic studies have examined factors related to serum Tg in large population-based settings (Krejbjerg et al, 2016;Ma and Skeaff, 5 2014), only one other study has examined factors related to Tg in a radiation exposed population with mild-to-moderate iodine deficiency (Cahoon et al, 2013).…”

Section: Most Studies Of Serum Tg Have Been Conducted Among Individuamentioning

confidence: 99%

Factors associated with serum thyroglobulin in a Ukrainian cohort exposed to iodine-131 from the accident at the Chernobyl Nuclear Plant

Peters

Тronko

Hatch

et al. 2017

Environmental Research

View full text Add to dashboard Cite

Background: Serum thyroglobulin (Tg) is associated with the presence of thyroid disease and has been proposed as a biomarker of iodine status. Few studies have examined factors related to serum Tg in populations environmentally exposed to ionizing radiation and living in regions with endemic mild-tomoderate iodine deficiency. Methods:We screened 10,430 individuals who were living in Ukraine and under 18 years of age at the time of the 1986 Chernobyl Nuclear Power Plant accident for thyroid disease from 2001 to 2003. We estimated the percent change (PC) in serum Tg associated with demographic factors, iodine-131 thyroid dose, and indicators of thyroid structure and function using linear regression. We also examined these relationships for individuals with and without indications of thyroid abnormality.Results: Mean and median serum Tg levels were higher among participants with abnormal thyroid structure/function. Percent change in serum Tg increased among females, smokers and with older age (pvalues < 0.001), and Tg increased with increasing thyroid volume, and serum thyrotropin (p-values for trend < 0.001). We found no evidence of significant associations between iodine-131 thyroid dose and Tg. Serum Tg levels were inversely associated with iodized salt intake (PC= -7.90, 95% confidence interval: -12.08, -3.52), and over the range of urinary iodine concentration, the odds of having elevated serum Tg showed a U-shaped curve with elevated Tg at low and high urinary iodine concentrations. Conclusion:Serum Tg may be a useful indicator of population iodine status and a non-specific biomarker of structural and functional thyroid abnormalities in epidemiological studies.

show abstract

“…The ablation rate was similar in the groups despite the thyrotropin stimulation method used, and the authors concluded that the use of rhTSH could be sufficient for the management of low-risk patients. In addition, short-term recurrence rates have been found to be similar in patients prepared with thyroid hormone withdrawal or rhTSH both in low-risk [50,51] and intermediate-risk patients [52]. The preparation with rhTSH significantly improves quality of life [46, 53] and reduces both whole-body irradiation [54,55] and hospitalization time [56].…”

Section: Radioiodine Dosing and Treatment Procedures Preparation For mentioning

confidence: 99%

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Castagna

Cantara

Pacini

2016

J Endocrinol Invest

View full text Add to dashboard Cite

Radioactive iodine therapy is administered to patients with differentiated thyroid cancer (DTC) for eradication of thyroid remnant after total thyroidectomy or, in patients with metastatic disease, for curative or palliative treatment. In past years, thyroid remnant ablation was indicated in almost every patient with a diagnosis of DTC. Nowadays, careful revision of patients' outcome has introduced the concept of risk-based selection of patients candidate to thyroid remnant ablation. The present review aims to underline the indications for thyroid remnant ablation and to address methodologies to be employed.

show abstract

Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up

Abstract: Long-term outcomes are similar in DTC patients treated with 1.1 GBq (30 mCi) ¹³¹I and prepared either with rhTSH or endogenous TSH. It is of interest that serum thyroglobulin at first control after ablation can have a prognostic role.

Cited by 61 publications

References 33 publications

Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?

Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?

Factors associated with serum thyroglobulin in a Ukrainian cohort exposed to iodine-131 from the accident at the Chernobyl Nuclear Plant

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Contact Info

Product

Resources

About